Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02117648 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2835219 in Participants With Cancer
A Phase 1 study of Neoplasm Metastasis and Neoplasm, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT02117648: Completed Phase 1 study of Neoplasm Metastasis and Neoplasm, sponsored by Eli Lilly and Company.
NCT02117648 is a Phase 1 study of Neoplasm Metastasis and Neoplasm that has completed, run by Eli Lilly and Company. The registered enrollment target is 26 participants, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02117648, a Phase 1 study of Neoplasm Metastasis and Neoplasm, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess how the body handles Abemaciclib when it is given with another drug called clarithromycin. The study doctor will measure the amount of Abemaciclib that is absorbed into the blood stream and the time that it takes to remove Abemaciclib from the body. The safety and tolerability of these drugs will be studied. Each participant will complete 2 study periods in fixed order. After screening, Period 1 will last approximately 8 days and Period 2 will last approximately 15 days. Participants who complete Period 2 may continue to receive Abemaciclib in 28-day cycles until discontinuation criteria are met.
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Clarithromycin
Study Locations (2)
Tennessee
- Accelerated Comm. Oncology Research Network (ACORN) - Memphis
- The West Clinic - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
What the finished NCT02117648 record still lists
NCT02117648 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 2 interventions - of which Abemaciclib is the first listed.
NCT02117648 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02117648 about?
NCT02117648 is a clinical study titled "A Study of LY2835219 in Participants With Cancer". The purpose of this study is to assess how the body handles Abemaciclib when it is given with another drug called clarithromycin. The study doctor will measure the amount of Abemaciclib that is absorbed into the blood stream and the time that it takes to remove Abemaciclib from the body. The safety ...
What is the current status of trial NCT02117648?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2014-04. Estimated completion is 2015-08.
What conditions does trial NCT02117648 study?
This clinical trial studies the following conditions: Neoplasm Metastasis, Neoplasm.
What interventions are being tested in trial NCT02117648?
The interventions under investigation include: Abemaciclib (DRUG), Clarithromycin (DRUG).
Who is sponsoring clinical trial NCT02117648?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02117648 being conducted?
This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02117648's enrollment target sits among peer trials
26 37th of 41 higher than 5 of 41 other Neoplasm Metastasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasm Metastasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
RECRUITING · Phase 1
-
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia